PT - JOURNAL ARTICLE AU - Lee, Karla A. AU - Ma, Wenjie AU - Sikavi, Daniel R. AU - Wolf, Jonathan AU - Steves, Claire J. AU - Spector, Tim D. AU - Chan, Andrew T. AU - , TI - Cancer and risk of COVID-19 through a general community survey AID - 10.1101/2020.05.20.20103762 DP - 2020 Jan 01 TA - medRxiv PG - 2020.05.20.20103762 4099 - http://medrxiv.org/content/early/2020/05/26/2020.05.20.20103762.short 4100 - http://medrxiv.org/content/early/2020/05/26/2020.05.20.20103762.full AB - Background Data are limited on the risk of coronavirus disease 2019 (COVID-19) among individuals with cancer and whether cancer-related therapy exacerbates this risk.Methods We evaluated the risk for COVID-19 among patients living with cancer compared to the general community and whether cancer-related treatments influence this risk. Data were collected from the COVID Symptom Study smartphone application since March 24, 2020 (United Kingdom), March 29 (U.S.), and April 29, 2020 (Sweden) through May 8, 2020. We used multivariate-adjusted odds ratios (aORs) of a positive COVID-19 test as well as predicted COVID-19 infection using a validated symptom model.Results Among 23,266 participants with cancer and 1,784,293 without cancer, we documented 10,404 reports of a positive COVID-19 test. Compared to participants without cancer, those living with cancer had 62% increased risk of a positive COVID-19 test (95% CI: 1.37-1.91). Among patients with cancer, current treatment with chemotherapy/immunotherapy was associated with a nearly 2.5-fold increased risk of a positive test (aOR: 2.42; 95% CI: 1.81-3.25). The association between cancer and COVID-19 positivity was stronger among participants >65 years (aOR: 1.93; 95% CI: 1.51-2.46) compared to younger participants (aOR: 1.32; 95% CI: 1.06-1.64; Pinteraction <0.001); and among amles (aOR: 1.71; 95% CI: 1.36-2.15) compared to females (aOR; 95% CI: 1.14-1.79; Pinteraction =0.02).Conclusions Individuals with cancer had a significantly increased risk of infection compared to the general community. Those treated with chemotherapy or immunotherapy were particularly at-risk of infection.Trial Registration ClinicalTrials.gov NCT04331509Competing Interest StatementJW is an employee of Zoe Global Ltd. TDS is a consultant to Zoe Global Ltd. ATC previously served as an investigator on a clinical trial of diet and lifestyle using a separate mobile application that was supported by Zoe Global Ltd. Other authors have no conflict of interest to declare.Clinical TrialNCT04331509Funding StatementZoe provided in kind support for all aspects of building, running and supporting the tracking app and service to all users worldwide. King's College of London investigators (KAL, CJS, TDS) were supported by the Wellcome Trust and EPSRC (WT212904/Z/18/Z, WT203148/Z/16/Z, T213038/Z/18/Z), the NIHR GSTT/KCL Biomedical Research Centre, MRC/BHF (MR/M016560/1), and the Alzheimer's Society (AS-JF-17-011). ATC is the Stuart and Suzanne Steele MGH Research Scholar and Stand Up to Cancer scientist. An Evergrande COVID-19 Response Fund Award through the Massachusetts Consortium on Pathogen Readiness (MassCPR) and Mark and Lisa Schwartz also supported MGH investigators (WM, DRS, ATC). Support was also received from the Swedish Foundation for Strategic Research (LUDC-IRC 15-0067), the Swedish Heart-Lung Foundation and the Swedish research Council.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData collected in the app are being shared with other health researchers through the NHS-funded Health Data Research UK (HDRUK)/SAIL consortium, housed in the UK Secure e-Research Platform (UKSeRP) in Swansea. Anonymized data collected by the symptom tracker app can be shared with bonafide researchers via HDRUK, provided the request is made according to their protocols and is in the public interest (see https://healthdatagateway.org/detail/9b604483-9cdc-41b2-b82c-14ee3dd705f6). US investigators are encouraged to coordinate data requests through the COPE Consortium (www.monganinstitute.org/cope-consortium). Data updates can be found at https://covid.joinzoe.com.